BPC-157 Therapy
Support Natural Healing and Recovery
BPC-157 therapy at AlphaCare is a medically supervised peptide program designed to support the body’s natural healing and recovery processes. It is used cautiously, with defined goals and structured monitoring, as a short-term adjunctive therapy.
What Is BPC-157?
BPC-157 (Body Protection Compound) is a peptide derived from a protein found in the stomach. It has been studied for its potential role in tissue repair and inflammation modulation. At AlphaCare, BPC-157 is offered only under medical supervision and is never used as a replacement for appropriate medical care.
BPC-157 may be considered to support recovery from:
- Tendon or ligament injuries
- Muscle strains or soft-tissue injuries
- Joint pain with inflammatory features
- Delayed healing after injury or surgery
Most research on BPC-157 comes from laboratory and animal studies suggesting potential benefits for tissue healing and inflammation support. Human data are limited, and outcomes vary. Because of this, treatment is carefully monitored and continued only if meaningful benefit is observed.
Some patients notice improvement within 1–2 weeks, while others require the full
treatment period. Benefits may include reduced pain, improved movement, and faster
recovery.
How Is BPC-157 Taken?
- Usually once daily
- Typical treatment duration is 4–6 weeks
- Injection training is provided
Possible Side Effects
Most patients tolerate BPC-157 well. Possible side effects include mild injection site irritation, headache, or lightheadedness.
Why Choose AlphaCare for BPC-157 Therapy
BPC-157 is not FDA-approved, and human clinical data remain limited. Most research comes from laboratory and animal studies suggesting potential support for tissue healing and inflammation, while human outcomes vary. For this reason, AlphaCare uses a conservative, structured approach with defined treatment durations, clear goals, required follow-up visits, and established stop rules. We emphasize informed decision-making, realistic expectations, and continuing therapy only when meaningful benefit is observed.
Frequently Asked Questions.
No. BPC-157 is not FDA-approved.
No. It is a peptide.
Most patients use BPC-157 for 4–6 weeks.
No. It is an adjunctive therapy only.
When to Contact AlphaCare
Contact your provider if symptoms worsen, new symptoms develop, or no improvement is noted by your follow-up visit. Seek emergency care for any severe or concerning symptoms.